The Oncopig cancer model as a validated model for human hepatocellular carcinoma

Kwame A. Darfour-Oduro1, Arun K. De1, L. A. Rund1, Ron C. Gaba2,3, Charles E. Ray2,3, Regina M. Schwind1, Kyle M. Schachtschneider1,4, Kuldeep Singh5 and L. B. Schook1,3

1 Department of Animal Sciences, University of Illinois, Urbana, IL, USA; 2 Department of Radiology, University of Illinois Hospital and Health Sciences System Chicago, IL, USA; 3 University of Illinois Cancer Center, Chicago, IL, USA

4 Animal Breeding and Genomics Center, Wageningen University, Wageningen, The Netherlands; 5 Veterinary Diagnostic Laboratory, University of Illinois, Urbana, IL, USA

Introduction:
Hepatocellular carcinoma (HCC) is the most common form of liver cancer in adults. It is the fifth most common cancer globally and is increasing in incidence in the USA due to high prevalence of comorbidities including hepatitis C and non-alcoholic fatty liver disease as risk factors for HCC development. Current animal models for HCC are severely lacking, and have minimal applicability for translational to clinical practice. Pigs share many genetic and physiological similarities with humans. In a previous study, we created the Oncopig, a transgenic pig encoding Cre recombinase inducible porcine transgenes KrasG12D and TP53R167H, a commonly mutated oncogene and tumor suppressor found in over 50% of human cancers, respectively (1). Therefore we investigated the potential of developing a porcine model of human HCC.

Hypothesis:
The Oncopig model mimics human HCC providing an ideal translational research platform for improving detection, treatment and other unmet clinical needs for HCC.

Aims:
1. To validate the Oncopig as model for human HCC in terms of phenotype, tumor development and gene expression.
2. To determine the reproducibility of human HCC characteristics across three Oncopigs

Materials and methods
- Hepatocytes were isolated from the liver of 3 Oncopigs two of which were from the same litter
- The hepatocytes (pPH) from each Oncopig were transformed by addition of AdCre and injected into 3 SCID mice (a total of 9 mice) at passage 8 and cell number of 1x10⁶ of the transformed cells (pHCC)
- RNA was extracted from primary hepatocytes and transformed hepatocytes of each Oncopig
- The transformed hepatocytes were tested for the expression of KrasG12D and TP53R167H by RT-PCR
- RNA-seq was performed on Illumina HiSeq 2000
- The libraries were sequenced to a total read length of 100 bp from both ends (paired-end sequencing)
- Transcript quantification and alignment was performed using Cufflinks

Results:
- Table 1: RNA-seq statistics on Oncopigs
- Table 2: Number of DEGs in pHCC cell lines

Conclusions and implications:
- Cytological analysis revealed that pHCC cell lines were different from pPH cells and had microscopic similarities with human HCC: As seen in Figure 4, pHCC cells were polygonal in shape (A) whereas the pPH cells were elongated similar to human HCC (B). Both pPH cells (C) and pHCC cells (D) expressed cytokeratin whereas only pHCC cells expressed vimentin (F). pPH cells (E) did not express vimentin. Expression of both cytokeratin and vimentin is characteristic of human HCC and is indicative of the EMT transition. Histological analysis revealed pHCC cells had morphological (G) similarities with human HCC and also expressed cytokeratin (H) and vimentin (I).
- As observed in human HCC, pHCC cell lines expressed the transgenes KrasG12D and TP53R167H (Fig. 3) and showed a downregulation of hepatocyte genes (Fig. 4).
- DEGs revealed that pHCC cell lines had similar gene expression profile indicating replicability of direction of gene dysregulation in all 3 pHCC cell lines (Fig. 5).
- Oncogenic pathways and genes dysregulated in human HCC were dysregulated in pHCC cell lines (Fig. 6).
- We have established 3 Oncopig hepatocellular carcinoma cell lines which demonstrate reproducibility in recapitulating human HCC in terms of phenotype, tumor development and gene expression. In the future, it is anticipated that the Oncopig will enable us to test different HCC treatment techniques, and evaluate responses both radiographically and pathologically.

References:

Funding:
Rural Development Administration of the Republic of Korea 538 JNU Korea 2012-06052